H.C. Wainwright reiterates Alto Neuroscience stock rating at buy

H.C. Wainwright reiterated a Buy rating on Alto Neuroscience (ANRO) with a $60 price target. The stock is up 119% over the past year, trading at $31.15. The company reported Q3 2026 results, maintaining its 2027 Phase 2b readout timeline and 2030 cash runway. ALTO-207 trial results and FDA feedback are expected in late 2026 or early 2027. H.C. Wainwright raised its success probability for ALTO-207 to 40% and assigned a 5% probability to ALTO-203.

Original reporting
Published Nov 12, 2026, 11:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ANRO
Bullish
medium confidence
Mentioned
$ANRO
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ANROBullishMed
01

Why it matters

The analyst's higher target and rating could attract new buying interest, especially from investors focused on clinical‑stage biotech.

02

Market read

The rating upgrade is a catalyst for short‑term price movement in ANRO, with broader implications for the depression‑therapy biotech niche.

03

What to watch

Potential dilution from future financing needs and competition from other depression treatments.

Relevance 7/10Novelty 6/10Timing: today

Background

Alto Neuroscience reported Q3 2026 results, completed a Phase 1 trial of ALTO-207, and outlined its Phase 2b readout timeline. The analyst raised the probability of success for its lead program.

Company-level read

Ticker impact

$ANROBullishMedium confidence
Context

H.C. Wainwright reiterated a Buy rating on Alto Neuroscience and raised its price target to $60, reflecting updated success probabilities for its ALTO-207 program.

Expected impact

likely upward pressure as investors price in the higher target and improved success odds.

Evidence & confidence

The rating change is a fresh analyst action with a concrete new price target, which can move the share price in the short term.

Market effects

May boost sentiment toward biotech firms developing depression therapies.

Limited to U.S. biotech investors.

Low, as the news is company‑specific.

Counterpoint

The upgrade may be premature given the early stage of the trials and cash runway uncertainties.

Key entities

  • Alto Neuroscience

    Biotech firm developing ALTO-207 for treatment‑resistant depression.

  • H.C. Wainwright

    Equity research firm that issued the rating and price target.

Related articles

$ANROMed

Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights – PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) on track; topline data in 2H 2027 – – Phase 1 study results on the modified-release formulation of ALTO-20

$ANROMed

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights – ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoin

$ANROMed

Alto Neuroscience, Inc. (ANRO): Results of Operations and Financial Condition

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001999480 0001999480 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

$ORCLMed

Oracle says OpenAI contract is fully funded, addresses market financing scrutiny

Oracle (NYSE:ORCL) announced it has fully funded its cloud infrastructure contract with OpenAI, completing a $20B capital raise plan. The company addressed market scrutiny over financing, reiterating its commitment to positive free cash flow by H2 2028 and $30B annual free cash flow by 2029. Oracle also updated progress on its data center buildout, including sites for OpenAI's AI models.

$BCLIMed

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND